What are the indications for sotoraxib targeted drugs?

Sotorasib is an innovative drug targeting the KRAS G12C mutation. It is mainly used to treat patients with non-small cell lung cancer (NSCLC) carrying the KRAS G12C mutation. KRAS Mutations in the KRAS gene are common in a variety of cancers, especially non-small cell lung cancer, colorectal cancer, and pancreatic cancer. The KRAS G12C mutation is a specific genetic mutation that accounts for approximately 13% to 15% of all KRAS mutations in non-small cell lung cancer. As the world's first KRAS G12C mutation-targeted drug, sotoracib provides a new treatment option for patients with this type of mutation.

The primary indication for sotoracib is for patients with advanced or metastatic non-small cell lung cancer harboring theKRAS G12C mutation. Traditional treatments such as chemotherapy and immunotherapy have limited efficacy for some patients with KRAS G12C mutations. Sotoraxib selectively inhibits KRAS G12C protein activity, effectively blocking cancer cell proliferation signals, thereby inhibiting the growth and spread of tumors. Clinical trial data show that sotorasiib has good efficacy and tolerability in the treatment of KRAS G12C mutation-positive non-small cell lung cancer patients.

In addition to non-small cell lung cancer, KRAS G12C mutations have also been found in other solid tumors, such as colorectal cancer and pancreatic cancer. Although sotoracib is currently used primarily in non-small cell lung cancer, its use in other tumors harboring the KRAS G12C mutation is also under investigation. Clinical trials are exploring the efficacy of sotoracib against KRAS G12C mutated colorectal cancer and have initially shown some anti-tumor activity, suggesting the drug may be suitable for patients with other types of cancer.

In summary, sotorasiib provides a new treatment approach for patients with KRAS G12Cmutated non-small cell lung cancer and shows significant efficacy. With the deepening of clinical research, its indications may be expanded to include more carriers in the futureKRAS G12Cmutated solid tumors will bring survival benefits to more patients.